Highlights of weekly biotech stock moves

Regulatory, clinical and other milestones

Amgen Inc. (NASDAQ:AMGN) lost $1.51 to $59.35 on a newsy week. Partner Johnson & Johnson (NYSE:JNJ) said FDA lifted a clinical hold on a Phase II trial of fulranumab to treat cancer pain. The pharma said it is in discussions with the agency to resolve issues in the osteoarthritis (OA) indication, which remains on clinical hold.

Last December, FDA placed a clinical hold on the humanized IgG2 mAb against nerve growth factor (NGF) due to concerns that the anti-NGF class may be associated with rapidly progressive osteoarthritis or osteonecrosis.

Separately, partner Daiichi Sankyo Co. Ltd. (Tokyo:4568; Osaka:4568) announced a deal with AstraZeneca plc (LSE:AZN; NYSE:AZN) to co-promote denosumab in Japan

Read the full 1088 word article

How to gain access

Continue reading with a
two-week free trial.